CSIMarket


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 


 

X4 Pharmaceuticals Inc

XFOR's Financial Statements and Analysis



X4 Pharmaceuticals Inc increased first quarter of 2024 net loss per share of $-0.26 compare to net loss per share of $-0.18 recorded in the same quarter a year ago a decrease compare to $-0.01 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.26 $  0 Mill
$-0.08     Unch.    



X4 Pharmaceuticals Inc's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


X4 Pharmaceuticals Inc is

More on XFOR's Income Statement



X4 Pharmaceuticals Inc in the first quarter of 2024 recorded net loss of $-51.766 million, an increase from net loss of $-29.104 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on XFOR's Growth

X4 Pharmaceuticals Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-39 million, capital expenditures fell by -0.03473.53%, to $0 millions compare to same quarter a year ago

More on XFOR's Cash flow Statement


X4 Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period X4 Pharmaceuticals Inc payed $ -0.13 cash per share, on a free-cash flow basis .

Book value fell by -98.49 % sequentially to $0.01 per share, -44.47% of net loss per share in trailing twelve-month period were subtructed from shareholder value.


Company issued 3.00 million shares or 1.52 % in Mar 31 2024.


More on XFOR's Dividends

 Market Capitalization (Millions) 181
 Shares Outstanding (Millions) 200
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -134
 Cash Flow (TTM) (Millions $) -69
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




X4 Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period X4 Pharmaceuticals Inc had negative $ -0.13 cash flow per share, on a free-cash flow basis .

Book value fell by -98.49 % sequentially to $0.01 per share, -44.47% of net loss per share in trailing twelve-month period were subtructed from shareholder value.


Company issued 3.00 million shares or 1.52 % in Mar 31 2024.


More on XFOR's Balance Sheets

 Market Capitalization (Millions) 181
 Shares Outstanding (Millions) 200
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -134
 Cash Flow (TTM) (Millions $) -69
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about X4 Pharmaceuticals Inc Earnings

X4 Pharmaceuticals Inc Reveals Jaw-Dropping $-27.214 Million Operating Shortfall in Latest Report

As the July to September 30 2023 reporting season continues, the stock market has been buzzing with updates from various companies. Among ...

XFOR's Financial Strain Continues to Grow as Operating Shortfall Soars to $-25.805 Million in Q2 2023


Introduction
As we delve into the financial performance of X4 Pharmaceuticals Inc during the April to June 30, 2023 reporting season, shareholders are presented with some interesting insights. The company's operating shortfall witnessed a significant increase compared to the previous year, leading to a substantial net deficit. Let's examine these figures in detail and contextualize the current situation at the organization.
Operating Shortfall and Financial Performance
During the second quarter of 2023, X4 Pharmaceuticals Inc faced an operating shortfall of $-25.805 million. This figure, which represents the company's expenses exceeding its revenue, raises concerns among stockholders. Compar...

X4 Pharmaceuticals Inc Sees Rising Working Costs, Despite Positive Momentum in ROI Rankings

X4 Pharmaceuticals Inc, a growing player in the biotechnology and pharmaceuticals sector, recently released its financial results for the 12 months ending in the third quarter of 2022. The company recorded a cumulative net loss of $-96 million, resulting in a negative return on investment (ROI) of -100.77%. Compared to other companies in the healthcare sector, X4 Pharmaceuticals Inc ranks lower with only 132 companies showing a higher ROI.
However, the overall ranking for ROI has progressed throughout the year, with the company's current ranking at 1101 in the first quarter of 2023, compared to its ranking in the fourth quarter...


Date modified: 2024-05-08T15:34:55+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com